Page last updated: 2024-12-10

u 44069

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 44069: has contractile effect on rat pulmonary veins & arteries; a thromboxane-A2 mimetic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311386
CHEBI ID190660
MeSH IDM0091521

Synonyms (16)

Synonym
u-44069
9,11-dideoxy-9alpha,11alpha-epoxymethanoprostaglandin f2alpha
CHEBI:190660
(z)-7-[(1s,4r,5s,6r)-5-[(e,3s)-3-hydroxyoct-1-enyl]-2-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid
56985-32-1
u44069
u 44069
5-heptenoic acid, 7-((1s,4r,5s,6r)-5-((1e,3s)-3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)hept-6-yl)-, (5z)-
5-heptenoic acid, 7-(5-(3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)hept-6-yl)-, (1s-(1alpha,4alpha,5alpha(1e,3r*),6beta(z)))-
9,11-dideoxy-9alpha,11alpha-epoxymethanoprostaglandin f2alpha (u-44069)
9,11-dideoxy-9alpha,11alpha-epoxy-methanoprostaglandin f2alpha
mfcd00135237
9,11-epoxymethanoprostaglandin h2
DTXSID701347862
HY-121825
CS-0083507

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves for U-46619 and U-44069 were shifted to the right in a parallel manner, and daltroban had no significant effect on responses to norepinephrine, serotonin, angiotensin II, BAY K 8644, endothelin-(ET) 1, ET-2, or platelet-activating factor (PAF)."( Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat.
Babycos, CR; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD, 1992
)
0.28
" Following the administration of SQ 29,548, pressor responses to both U44069 and U46619 were reduced significantly, and the dose-response curves for both TXA2 mimics were shifted to the right in a parallel fashion."( Influence of SQ 29,548 on vasoconstrictor responses in the hindquarters vascular bed of the cat.
Bellan, JA; Kadowitz, PJ; McMahon, TJ; McNamara, DB; Minkes, RK, 1991
)
0.28
" The PAF receptor antagonism with BN 50730 was overcome when 10-fold larger doses of PAF were administered and the dose-response curves for changes in lung resistance and dynamic compliance were shifted to the right in a parallel manner."( Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
Beckerman, RC; Bellan, JA; Braquet, P; Dyson, MC; Kadowitz, PJ; McNamara, DB; Minkes, RK; Wegmann, MJ, 1990
)
0.28
" Dose-response curves were produced with the thromboxane-mimetics U46619 and U44069 (10(-10)-2 x 10(-6)M), arginine vasopressin (10(-10)-5 x 10(-8)M) and endothelin-1 (10(-11)-3 x 10(-7)M) in the presence or absence of 50 micromol l(-1) glibenclamide."( Glibenclamide inhibits agonist-induced vasoconstriction of placental chorionic plate arteries.
Baker, PN; Fyfe, GK; Greenwood, SL; Taggart, MJ; Wareing, M,
)
0.13
"Pre-incubation with 50 micromol l(-1) glibenclamide significantly right-shifted dose-response curves to all vasoconstrictive agonists tested (repeated measures ANOVA)."( Glibenclamide inhibits agonist-induced vasoconstriction of placental chorionic plate arteries.
Baker, PN; Fyfe, GK; Greenwood, SL; Taggart, MJ; Wareing, M,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (51.43)18.7374
1990's36 (34.29)18.2507
2000's12 (11.43)29.6817
2010's3 (2.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.85%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other106 (98.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]